Even after such a large drop in price, given around half the companies in China's Biotechs industry have price-to-sales ratios (or "P/S") below 7x, you may still consider Jiangsu Sihuan Bioengineering as a stock to avoid entirely with its 13.5x P/S ratio. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.